Author:
Appels N M G M,Bolijn M J,Chan K,Stephens T C,Hoctin-Boes G,Middleton M,Beijnen J H,de Bono J S,Harris A L,Schellens J H M
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM (2004) Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103 (9): 3271–3277
2. Appels NMGM, Beijnen JH, Schellens JHM (2005) Development of farnesyl transferase inhibitors; a review. Oncologist 10 (8): 565–578
3. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49 (17): 4682–4689
4. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ (2003) Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 63 (18): 5656–5668
5. Casey PJ, Seabra MC (1996) Protein prenyltransferases. J Biol Chem 271 (10): 5289–5292
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献